二甲双胍预防糖尿病的长期效果:DPP与DPPOS中获益最大亚组的识别
在DPP和DPPOS研究中,高危成人随机接受安慰剂或二甲双胍850mg每日两次,随访15年。二甲双胍分别基于血糖和HbA1c标准使糖尿病发病风险降低17%和36%;基线空腹血糖或HbA1c较高者以及有妊娠期糖尿病史的女性获益更大。
要点
- 二甲双胍15年随访降低糖尿病发病风险,血糖定义降17%,HbA1c定义降36%。
- 有妊娠期糖尿病史的女性获益更大,HR 0.59,率差-4.57例/100人年。
- 基线空腹血糖或HbA1c较高者获益更大,HbA1c 6.0-6.4%组率差-3.88例/100人年。
核心结论
- 二甲双胍在15年随访中降低糖尿病发生风险17%(血糖标准)或36%(HbA1c标准)。
- 获益最大的亚组包括基线空腹血糖或HbA1c较高者以及有妊娠期糖尿病史的女性。
研究设计与样本
- DPP研究(1996-2001)将糖尿病高危成人随机分配至安慰剂组(n=1,082)或二甲双胍850mg每日两次组(n=1,073)。
- DPPOS(2002-至今)中,原二甲双胍组继续接受非盲法二甲双胍治疗。
- 糖尿病诊断基于空腹血糖、口服葡萄糖耐量试验后2小时血糖或HbA1c。
主要发现
- 15年随访期间,二甲双胍较安慰剂降低糖尿病发病率17%(基于血糖)和36%(基于HbA1c)。
- 有妊娠期糖尿病史的女性,二甲双胍对血糖定义糖尿病的HR为0.59,率差-4.57例/100人年;无妊娠期糖尿病史经产妇HR 0.94,率差-0.38例/100人年(交互作用P=0.03 for HR,P=0.01 for RD)。
- 基线空腹血糖越高,二甲双胍的HR和率差效果越大。
- 基于HbA1c定义糖尿病时,基线HbA1c<6.0%(42 mmol/mol)组率差-1.03例/100人年,6.0-6.4%组率差-3.88例/100人年(P=0.0001)。
临床怎么用
- 对于糖尿病高危成人,尤其是有妊娠期糖尿病史或基线空腹血糖/HbA1c较高者,可考虑使用二甲双胍预防糖尿病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We examined the effects of metformin on diabetes prevention and the subgroups that benefited most over 15 years in the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS: During the DPP (1996-2001), adults at high risk of developing diabetes were randomly assigned to masked placebo (n = 1,082) or metformin 850 mg twice daily (n = 1,073). Participants originally assigned to metformin continued to receive metformin, unmasked, in the DPPOS (2002-present). Ascertainment of diabetes development was based on fasting or 2-h glucose levels after an oral glucose tolerance test or on HbA1c. Reduction in diabetes incidence with metformin was compared with placebo in subgroups by hazard ratio (HR) and rate differences (RDs). RESULTS: During 15 years of postrandomization follow-up, metformin reduced the incidence (by HR) of diabetes compared to placebo by 17% or 36% based on glucose or HbA1c levels, respectively. Metformin's effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD -4.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD -0.38 cases/100 person-years [interaction P = 0.03 for HR, P = 0.01 for RD]). Metformin also had greater effects, by HR and RD, at higher baseline fasting glucose levels. With diabetes development based on HbA1c, metformin was more effective in subjects with higher baseline HbA1c by RD, with metformin RD -1.03 cases/100 person-years with baseline HbA1c <6.0% (42 mmol/mol) and -3.88 cases/100 person-years with 6.0-6.4% (P = 0.0001). CONCLUSIONS: Metformin reduces the development of diabetes over 15 years. The subsets that benefitted the most include subjects with higher baseline fasting glucose or HbA1c and women with a history of GDM.
引用
- Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019. PMID: 30877090. doi:10.2337/dc18-1970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。